US court's decision in AMP v USPTO advances personalised medicine
This article was originally published in RAJ Devices
Executive Summary
Roger D Klein says the federal district court's decision to invalidate patent claims for BRCA1 and BRCA2 is an important first step in eliminating unjustifiable restrictions that would otherwise harm patients.